Immunohistochemical evaluation of caspase 3 expression in rats' hepatocytes after L-arginine therapy

• Autorzy: Pedrycz A , Kot K. , Olesinski I.
• Języki publikacji: EN

Abstrakty

EN

The apoptotical effect of nitric oxide on effector apoptotical caspase 3 in rats' hepatocytes was examined. The experiment was performed on 16 white Wistar female rats divided into two equal groups. The rats from the experimental group received orally L-arginine in a dose of 40 mg/kg b.w. every other day for 2 weeks. The rats from the control group received orally 2 ml of distilled water in the same manner as the experimental group. All the rats were decapitated after 3 weeks of the experiment. After decapitation, specimens from the liver were collected, fixed in 10% formalin, and then embedded in paraffin blocks. Protein caspase 3 on slides was detected using the standard three-step immunohistochemical method. The quantitative evaluation of caspase 3 expression showed that the area occupied by positive caspase 3 reaction in the liver of the experimental group (128.11 µm²±96.54) was comparable to that in the control group (212.18 µm² ±1 16.59) (P=0.25). The dose of L-arginine used was similar to that applied in pregnant women treated for gestosis. The study shows that L-arginine as a donor of exogenous nitric oxide has no an apoptotic effect on rats' hepatocytes.

Słowa kluczowe

EN

rat; hepatocyte; liver; apoptosis; L-arginine; caspase-3; nitric oxide

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2010
• Tom: 54
• Numer: 1
• Opis fizyczny: p.101-103,fig.,ref.

Twórcy

autor

Pedrycz A

• Medical University of Lublin, 20-442 Lublin, Poland

autor

Kot K.

autor

Olesinski I.

Bibliografia

• 1. Ali J., Panchal N., Li D., Gan Y.: Apoptosis: A new pharmacodynamic endopoint. Pharm Res 1997, 14, 1659-1668.
• 2. Appleton J.: Arginine: Clinical potential of a semiessential amino. Altern Med Rev 2002, 7, 512-522.
• 3. Cherla G., Jaimes E.A.: Role of L-arginine in the pathogenesis and treatment of renal disease. J Nutr 2004, 134, 2801S-2806S.
• 4. Chmielewski M., Linke K., Zabel M., Szuber L.: Apoptosis in the liver. Gastroent Pol 2003, 10, 453-462.
• 5. Cryns V., Yuan J.: Proteases to die for. Genes Dev 1998, 12, 1551-1570.
• 6. Domiński Z.: Apoptosis: cell death in animal's life. Kosmos 1999, 48, 385-396.
• 7. Enari M., Talanian R.V., Wong W.W., Nagata S.: Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996, 380, 723-726.
• 8. Eu J.P., Liu L., Zeng M., Stamler J.S.: An apoptotic model for nitrosative stress. Biochemistry 2000, 39, 1040-1047.
• 9. Fabbi M., Marimpietri D., Martini S., Brancoloni C., Amoresano A., Scaloni A., Bargellesi A., Cosulich E.: Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ 1999, 6, 992-1001.
• 10. Furchgott R.F.: Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 1999, 19, 235-251.
• 11. Izdebska M., Grzanka A., Ostrowski M.: Cancer of the urinary bladder - the molecular base of the genesis and the treatment. Kosmos 2005, 54, 213-220.
• 12. Kiliańska Z.M., Miskiewicz A.: The caspases of the vertebrates; their role in the apoptosis. Post Biol Kom 2003, 30, 129-151.
• 13. Kothakota S., Azuma T., Reinhard C., Klippel A., Tang J., Chiu K., McGarry T.J., Kirschner M.W., Koths K., Kwiatkowski D.J., Williams L.T.: Caspase 3 generated fragment of gelsolin: effector of morfological change in apoptosis. Science 1997, 278, 294-298.
• 14. Kronon M.T., Allen B.S., Halldorsson A., Rahman S., Wang T., Ilbawi M.: Dose dependency of L-arginine in neonatal myocardial protection: the nitric oxide paradox. Thorac Cardiovasc Surg 1999, 118, 655-664.
• 15. Liu X., Zou H., Slaughter C., Wang X.: DFF, a heterodimetric protein that functions downstream of caspase-3 to tigger DNA fragmentation during apoptosis. Cell 1997, 89, 175-184.
• 16. Maleck W.H., Piper S.N., Koetter K.: Joseph Priestley, nitrous oxide and oxygen. Anaesthesist 2005, 54, 395- 396.
• 17. Rytlewski K., Olszanecki R., Korbut R., Zdebski Z.: Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest 2005, 35, 32-37.
• 18. Rytlewski K., Zdebski Z.: Nitric oxide - one of the mechanisms that prevent changes that occur during pregnancy. Ginekol Pol 2001, 72, 738-743.
• 19. Severinghaus J.W.: Fire-air and dephlogistication. Revisionisms of oxygen's discovery. Adv Exp Med Biol 2003, 543, 7-19.
• 20. Sternbach G.L., Varon J.: The discovery and rediscovery of oxygen. J Emerg Med 2005, 28, 221-224.
• 21. Wright A.J. : Joseph Priestley's "factitious airs" and medical therapy before 1800: a brief review. Bull Anesth Hist 2000, 18, 4-6.